Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pinealoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Meningioma 1Medulloblastoma 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Ependymoma 1Craniopharyngioma 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Breast Neoplasms 1Astrocytoma 1

Interventions

Paclitaxel 28Trastuzumab 22Cyclophosphamide 21Doxorubicin 14Docetaxel 14Carboplatin 11exemestane 10Radiotherapy 10Letrozole 10Capecitabine 10pembrolizumab 8Lapatinib 8Fulvestrant 8Neoadjuvant Therapy 6Goserelin 6Bevacizumab 6Anastrozole 6pertuzumab 5palbociclib 5eribulin 5abemaciclib 5Therapeutics 5Magnetic Resonance Spectroscopy 5Epirubicin 5Chemotherapy, Adjuvant 5Aromatase Inhibitors 5tucatinib 4Vinorelbine 4Taxes 4Tamoxifen 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Breast Neoplasms × Gadolinium DTPA × Clear all
NCT00373152 2017-12-05

MRI in Predicting Tumor Reponse After Radiofrequency Ablation in Women With Invasive Breast Cancer

Masonic Cancer Center, University of Minnesota

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡